alexa Mesothelin Expression In Ovarian Cancer And Its Potential As Targeted Ovarian Cancer Immunotherapy
ISSN: 2157-7552

Journal of Tissue Science & Engineering
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

Global Congress on Tissue Engineering, Regenerative & Precision Medicine
December 1-2, 2016 | San Antonio, USA

Samir A. Farghaly
Cornell University, USA
Posters & Accepted Abstracts: J Tissue Sci Eng
DOI: 10.4172/2157-7552.C1.031
Abstract
Ovarian cancer is the fourth most common cause of cancer death in women. Most patients are diagnosed at stage III and IV, with resultant low relative-survival rates. The current treatments with conventional cytotoxic chemotherapy and novel surgical techniques have improved the oncologic outcome of this disease. However, recurrence is common. Current evidence suggests that the immune system and its ability to recognize and eliminate the microscopic disease is of significant importance in preventing recurrence. Immunotherapy for ovarian cancer is to balance the activation of the immune system against this cancer while preventing the potential for toxicity elicited by immune modulation. Mesothelin, a glycosylphosphatidylinositol (GPI) anchored cell surface protein, is a potential target for antibody-based ovarian cancer immunotherapy due to its high expression in ovarian cancer. Human monoclonal antibodies targeting mesothelin have been isolated by phage display technology and it provides opportunities for novel ovarian cancer immunotherapy. In addition, CRS-207 is live-attenuated Listeria monocytogenes (Lm), which has been genetically modified to be safe for human use while retaining its ability to stimulate an immune response against the protein mesothelin.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords